Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
OXiGENE shares rose in pre-market trading Monday
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
ImmunoCellular Therapeutics will present positive results from a phase 1 clinical study on its ICT-107 therapy, a treatment for a type of brain tumor.
The fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by UV exposure or excessive sun burn.
Threshold Pharmaceuticals takes advantage of the differences in metabolic activity between cancerous and normal, healthy biological tissue.
Provectus Pharmaceuticals develops a powerful drug pipeline with minimal side effects, including a cancer drug that targets cancer tissue, as well as…
Strategic News Service recently announced that Cynvenio Biosystems has been selected as a 2011 FiReStarter company, to be featured at its annual Future in Review technology conference.
Copyright © 2025 | WordPress Theme by MH Themes